• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

剑桥肺动脉高压结局评估(CAMPHOR):一项针对肺动脉高压患者健康相关生活质量和生活质量的评估指标。

The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension.

作者信息

McKenna S P, Doughty N, Meads D M, Doward L C, Pepke-Zaba J

机构信息

Galen Research, Enterprise House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, UK.

出版信息

Qual Life Res. 2006 Feb;15(1):103-15. doi: 10.1007/s11136-005-3513-4.

DOI:10.1007/s11136-005-3513-4
PMID:16411035
Abstract

OBJECTIVE

No outcome measures specific to pulmonary hypertension (PH) currently exist. The aim of the study was to develop health-related quality of life (symptoms and functioning) scales and a quality of life scale that would allow comprehensive, accurate and valid patient-reported outcome assessment in clinical studies.

METHODS

The content of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) was derived from qualitative interviews conducted with 35 patients. Item reduction was based on the analysis of responses to a postal survey (n=75) and patient interviews (n=15) designed to determine face and content validity. A final postal validation study (n=91) was performed to determine reproducibility and construct validity.

RESULTS

The questionnaire was well received by participants who found it to be relevant, comprehensible and quick and easy to complete. Rasch and factor analyses were conducted to ensure unidimensionality of the final CAMPHOR scales; Overall symptoms (made up of Energy, Breathlessness and Mood subscales), Functioning and Quality of life. The CAMPHOR scales had good internal consistency (alpha=0.90-0.92) and reproducibility (test-retest correlations=0.86-0.92). They also exhibited convergent, divergent and known groups validity.

CONCLUSIONS

The CAMPHOR is a valuable new instrument for assessing patient-reported outcome in PH clinical trials and routine practice.

摘要

目的

目前尚无专门针对肺动脉高压(PH)的结局指标。本研究的目的是开发与健康相关的生活质量(症状和功能)量表以及生活质量量表,以便在临床研究中进行全面、准确且有效的患者报告结局评估。

方法

剑桥肺动脉高压结局评估(CAMPHOR)的内容源自对35名患者进行的定性访谈。基于对旨在确定表面效度和内容效度的邮寄调查问卷(n = 75)及患者访谈(n = 15)的回答分析进行项目精简。开展了一项最终的邮寄验证研究(n = 91)以确定可重复性和结构效度。

结果

参与者对该问卷评价良好,认为其相关、易懂且填写快速简便。进行了拉施分析和因子分析以确保最终的CAMPHOR量表具有单维性;总体症状(由精力、呼吸困难和情绪子量表组成)、功能和生活质量。CAMPHOR量表具有良好的内部一致性(α = 0.90 - 0.92)和可重复性(重测相关性 = 0.86 - 0.92)。它们还表现出收敛效度、区分效度和已知群组效度。

结论

CAMPHOR是一种有价值的新工具,可用于评估PH临床试验和常规实践中的患者报告结局。

相似文献

1
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension.剑桥肺动脉高压结局评估(CAMPHOR):一项针对肺动脉高压患者健康相关生活质量和生活质量的评估指标。
Qual Life Res. 2006 Feb;15(1):103-15. doi: 10.1007/s11136-005-3513-4.
2
Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden.瑞典剑桥肺高血压结局研究的改编和验证。
Scand J Public Health. 2012 Dec;40(8):777-83. doi: 10.1177/1403494812464445. Epub 2012 Oct 31.
3
Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Use in Spain.适用于西班牙的《剑桥肺动脉高压结局评估》(CAMPHOR)的改编与验证
Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):467-473. doi: 10.1016/j.rec.2016.11.007. Epub 2016 Dec 15.
4
Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.剑桥肺动脉高压结局评估(CAMPHOR)问卷的葡萄牙语验证
Health Qual Life Outcomes. 2016 Jul 26;14(1):110. doi: 10.1186/s12955-016-0513-8.
5
ADAPTATION AND VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) FOR CROATIA.《剑桥肺动脉高压结局评估量表(CAMPHOR)》在克罗地亚的适应性调整与验证
Acta Clin Croat. 2019 Mar;58(1):3-12. doi: 10.20471/acc.2019.58.01.01.
6
United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).美国对剑桥肺动脉高压结局评估(CAMPHOR)的验证。
J Heart Lung Transplant. 2008 Jan;27(1):124-30. doi: 10.1016/j.healun.2007.10.004.
7
The Polish adaptation of the CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR).波兰版剑桥肺高压预后评估(CAMPHOR)。
Cardiol J. 2020;27(5):608-615. doi: 10.5603/CJ.a2018.0119. Epub 2018 Oct 19.
8
Cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review for use in patients with pulmonary hypertension in Colombia.跨文化适应的剑桥肺高血压结局研究在哥伦比亚肺高血压患者中的应用。
J Bras Pneumol. 2019 Jul 29;45(6):e20180332. doi: 10.1590/1806-3713/e20180332.
9
Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population.验证剑桥肺高血压结局研究(CAMPHOR)在澳大利亚和新西兰人群中的适用性。
Respirology. 2011 Nov;16(8):1235-40. doi: 10.1111/j.1440-1843.2011.02030.x.
10
Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension.CAMPHOR 和 SF-36 在肺动脉高压中的心理计量学性能。
BMC Pulm Med. 2013 Jul 12;13:45. doi: 10.1186/1471-2466-13-45.

引用本文的文献

1
Prognostic Value of Pulmonary Hypertension as an Incidental Finding Detected by Echocardiography in Patients Without Known Cardiovascular or Pulmonary Diseases.超声心动图偶然发现的肺动脉高压在无已知心血管或肺部疾病患者中的预后价值
J Clin Med. 2025 Jul 16;14(14):5044. doi: 10.3390/jcm14145044.
2
The PAH patient's perspective.肺动脉高压患者的观点。
Int J Cardiol Congenit Heart Dis. 2025 May 26;21:100596. doi: 10.1016/j.ijcchd.2025.100596. eCollection 2025 Sep.
3
Effects of postoperative rehabilitation on functional exercise capacity, dyspnea, and quality of life after pulmonary endarterectomy: a systematic review.

本文引用的文献

1
The Development and Psychometric Properties of the MSQOL: A Migraine-Specific Quality-of-Life Instrument.《MSQOL:偏头痛特异性生活质量量表的制定与心理测量学特性》。
Clin Drug Investig. 1998;15(5):413-23. doi: 10.2165/00044011-199815050-00006.
2
International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD).特应性皮炎患者生活质量父母指数(PIQoL-AD)的国际发展情况。
Qual Life Res. 2005 Feb;14(1):231-41. doi: 10.1007/s11136-004-4231-z.
3
Application of Rasch analysis in the development and application of quality of life instruments.
肺内膜剥脱术后康复对功能运动能力、呼吸困难及生活质量的影响:一项系统评价
J Yeungnam Med Sci. 2025;42:32. doi: 10.12701/jyms.2025.42.32. Epub 2025 Apr 10.
4
Patients' perspectives on the challenges associated with receiving non-oral pulmonary arterial hypertension treatment: a mixed methods study.患者对接受非口服肺动脉高压治疗相关挑战的看法:一项混合方法研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241289807. doi: 10.1177/17534666241289807.
5
Exploring the patient perspective in pulmonary hypertension.探讨肺动脉高压中的患者视角。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01129-2024. Print 2024 Oct.
6
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.肺动脉高压的临床试验设计、终点和新兴疗法。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01205-2024. Print 2024 Oct.
7
Quality of life in oncological patients with venous thromboembolic disease.患有静脉血栓栓塞性疾病的肿瘤患者的生活质量。
Res Pract Thromb Haemost. 2024 Jul 14;8(5):102510. doi: 10.1016/j.rpth.2024.102510. eCollection 2024 Jul.
8
Assessing quality of life in pulmonary arterial hypertension: An independent prognostic marker.评估肺动脉高压患者的生活质量:一项独立的预后标志物。
Pulm Circ. 2024 Jun 2;14(2):e12380. doi: 10.1002/pul2.12380. eCollection 2024 Apr.
9
The one-minute sit-to-stand-test performance is associated with health-related quality of life in patients with pulmonary hypertension.一分钟坐站测试表现与肺动脉高压患者的健康相关生活质量相关。
PLoS One. 2024 May 29;19(5):e0301483. doi: 10.1371/journal.pone.0301483. eCollection 2024.
10
Exploratory and confirmatory factor analysis of emPHasis-10: The health-related quality-of-life measure in pulmonary hypertension.“强调-10”的探索性和验证性因素分析:肺动脉高压中与健康相关的生活质量测量指标
Pulm Circ. 2024 May 12;14(2):e12378. doi: 10.1002/pul2.12378. eCollection 2024 Apr.
拉施分析在生活质量量表开发与应用中的应用
Value Health. 2004 Sep-Oct;7 Suppl 1:S22-6. doi: 10.1111/j.1524-4733.2004.7s106.x.
4
The needs-based approach to quality of life assessment.基于需求的生活质量评估方法。
Value Health. 2004 Sep-Oct;7 Suppl 1:S1-3. doi: 10.1111/j.1524-4733.2004.7s101.x.
5
Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.接受长期依前列醇治疗的肺动脉高压患者的皮肤表现
J Am Acad Dermatol. 2004 Jul;51(1):98-102. doi: 10.1016/j.jaad.2003.12.032.
6
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis.银屑病关节炎生活质量量表(PsAQoL)的开发:一种针对银屑病关节炎的生活质量评估工具。
Ann Rheum Dis. 2004 Feb;63(2):162-9. doi: 10.1136/ard.2003.006296.
7
Prostanoids for pulmonary arterial hypertension.用于肺动脉高压的前列腺素类药物
Am J Respir Med. 2003;2(2):123-37. doi: 10.1007/BF03256644.
8
Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.银屑病生活质量量表(PSORIQoL)的开发,这是一种专为临床实践和试验设计的银屑病特异性生活质量测量工具。
Br J Dermatol. 2003 Aug;149(2):323-31. doi: 10.1046/j.1365-2133.2003.05492.x.
9
Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis.强直性脊柱炎生活质量量表(ASQoL)的开发:一种针对强直性脊柱炎的生活质量评估工具。
Ann Rheum Dis. 2003 Jan;62(1):20-6. doi: 10.1136/ard.62.1.20.
10
Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial.健康相关生活质量评估与医患沟通:一项随机对照试验。
JAMA. 2002 Dec 18;288(23):3027-34. doi: 10.1001/jama.288.23.3027.